MSD Animal Health
We believe, with deepening awareness that animal safety and human health are closely linked, Animal Health will have even better prospects for development with innovative high-quality animal drugs, vaccines, smart devices and services.
In Mainland China
MSD Animal Health has nearly 600 employees in China, with headquarters in Shanghai, factories in Ningbo and Tianjin, and R&D center in Ningbo
MSD Animal Health is made up of four business units: Poultry, Swine, Companion Animal, and Ruminant, which provides close to 60 products in our portfolio. We are committed to becoming a close partner of veterinarians, farmers and pet owners, improving animal health and benefiting Chinese society
Tianjin Ringpu Bio-Technology Co., Ltd. (referred to as "Ringpu"), founded in 1998, owns a total of 21 branch and subsidiary companies, 10 GMP approved production bases for veterinary drugs and 1 large-scale feed additive production base, 98 intelligent and modern large-scale production lines, and more than 500 kinds of animal products covering livestock, poultry and companion animals. It is China's largest manufacturer and service provider of animal health products with the most comprehensive product range, integrating biological products, pharmaceutical raw materials, pharmaceutical preparations and feed additives.
Bioally is the only domestic high-tech enterprise in China focused on developing, producing, and selling innovative drugs and functional healthcare products for pets. It has invested 250 million RMB to build a 24,000 square meter industrial base in Taizhou, China's Pharmaceutical City, meeting EU standards. In December 2023, it received approval for "Boshenjian," the world's first canine albumin .
Founded in 1956, HISUN PHARM is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. HISUN PHARM has 5 facilities, over 600 research staffs , over 60 unit labs，over 1100 patent applications (including 500+ invention patents) , which provides innovative results and quality products for the industry. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times.
As the holding subsidiary of HISUN PHARM, HISUN ANIMAL HEALTH (HISUNAH) inherits HISUN spirits and drug quality，has two production bases of Fuyang Chemical and Kunming Vaccine investing 800 million, which established lots of production lines （certificated by GMP and APVMA）. HISUNAH devotes to R&D, manufacture, sales and service, provides health solution for farm animal and companion animal. HISUNAH, live for animal health!
MISSON: INSIST ON DRUG INNOVATION, ACHIEVE HEALTH DREAM
VISION: TO BE A WIDELY RESPECTED GLOBAL PHARMACEUTICAL COMPANY
Slogan：Innovation，for animals，for health，for you.
Hanvet Biopharmaceutical Technology Co., Ltd. was established in 2008 and is located in Zhangjiang, Shanghai, known as "China's Silicon Valley". It is an internationally advanced high-tech enterprise integrating research, production, and sales of pet healthcare products. It has been recognized as a high-tech enterprise by the State three times in a row.
Hanvet has always adhered to the corporate values of "integrity, sincerity, dedication, innovation-driven, customer first, partner growth", deeply cultivating fields such as pet anti-infection, skin, urinary, fever and pain relief, and intestinal and external parasite control, as well as feline diseases, to provide systematic solutions and professional services for customers in the pet-specific new drugs, health care and care products.
The company strictly follows the international VICH & ICH guidelines to establish a professional animal drug R&D and testing center with a complete quality system; it builds factories in accordance with China's GMP and international GMP standards to provide 100% fully compliant pet-specific drugs.
To date, Hanvet has obtained 46 pet drug approvals, obtained 30 patent authorizations, 11 national new veterinary drug certificates, and contract-researched more than 30 formulas for international customers. With its trusted product quality and persistent investment in R&D, Hanwei Chongshi has become the loyal choice of more than 10,000 professional pet hospitals and has become "the pioneer of professional pet drugs in China".
Based in China and looking globally. Hanvet is committed to providing systematic solutions to safeguard pet health and build a harmonious world of human-pet friendship!
